Page last updated: 2024-11-06

anisodamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Anisodamine is a tropane alkaloid extracted from the roots of the plant Anisodus tanguticus. It is structurally similar to atropine and scopolamine and possesses similar pharmacological effects. It is used in traditional Chinese medicine for its antispasmodic and analgesic properties. Anisodamine has been studied for its potential therapeutic effects in a range of conditions, including:

- Asthma: Anisodamine has bronchodilator effects, similar to other anticholinergics.
- Parkinson's disease: Anisodamine has been investigated for its potential to reduce tremors and rigidity in Parkinson's patients.
- Cancer: Some preliminary research suggests that anisodamine may have anti-tumor activity against certain types of cancer.
- Pain management: Anisodamine has been used to relieve pain, especially in conditions like rheumatoid arthritis.

Anisodamine is synthesized from the plant material through extraction and purification processes. It has been used in clinical practice for several decades, although research into its mechanisms and long-term effects is ongoing.'

anisodamine: alkaloid isolated from Chinese solanacea plant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64704
MeSH IDM0045052
PubMed CID6918612
CHEMBL ID2165224
MeSH IDM0045052

Synonyms (41)

Synonym
55869-99-3
anisodamine
[(3s,6s)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2s)-3-hydroxy-2-phenylpropanoate
3-bicyclo[3.2.1]octanyl 3-hydroxy-2-phenyl-propanoate
SBI-0051252.P002
39459-41-1
DTXSID60960095
benzeneacetic acid, alpha-(hydroxymethyl)-, (1r,3s,5r,6s)-6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (alphas)-
benzeneacetic acid, alpha-(hydroxymethyl)-, 6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (1r-(1-alpha,3-beta(s*),5-alpha,6-alpha))-
alpha-(hydroxymethyl)benzeneacetic acid 6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester
[(1r,3s,5r,6s)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2s)-3-hydroxy-2-phenylpropanoate
AKOS015955736
unii-01343q8el8
01343q8el8 ,
654-ii
hyoscyamine, 6-hydroxy-
6.beta.-hydroxyhyoscyamine
CHEMBL2165224
(-)-6.beta.-hydroxyhyoscyamine
anisodamine [mart.]
benzeneacetic acid, .alpha.-(hydroxymethyl)-, (1r,3s,5r,6s)-6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (.alpha.s)-
anisodamine [who-dd]
CCG-221772
CS-4549
WTQYWNWRJNXDEG-RBZJEDDUSA-N
HY-N0584
(s)-3-hydroxy-2-phenyl-propionic acid (1r,3s,5r,6s)-6-hydroxy-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester, aldrichcpr
NCGC00485098-01
DB11785
NCGC00485098-02
[(1s,3s,5s,6s)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
MS-24415
benzeneacetic acid, alpha-(hydroxymethyl)-, (1r,3s,5r,6s)-6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (alphas)-rel-
anisodamine, (+/-)-
unii-u5ac4zpq36
u5ac4zpq36 ,
raceanisodamine [who-dd]
85760-60-7
DTXSID301025872
benzeneacetic acid, .alpha.-(hydroxymethyl)-, (1r,3s,5r,6s)-6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (.alpha.s)-rel-
GLXC-25555

Research Excerpts

Overview

Anisodamine is an anticholinergic drug extracted and isolated from the Anisodus tanguticus (Maxim.) Pascher of the Solanaceae family. The belladonna alkaloid is non subtype-selective muscarinic and a nicotinic cholinoceptor antagonist, which has been employed in traditional Chinese medicine.

ExcerptReferenceRelevance
"Anisodamine is an agent extracted from traditional Chinese medicine with potent anti-inflammatory effects."( Effectiveness of anisodamine for the treatment of critically ill patients with septic shock: a multicentre randomized controlled trial.
Chen, L; Gao, Y; Hong, Y; Hu, C; Huang, Z; Liu, D; Ren, B; Tian, X; Wang, X; Yin, R; Yu, Y; Zhang, C; Zhang, Z; Zhou, J; Zhu, C, 2021
)
1.68
"Anisodamine is an anticholinergic drug extracted and isolated from the Anisodus tanguticus (Maxim.) Pascher of the Solanaceae family which is also a muscarinic receptor antagonist. "( Update on the sources, pharmacokinetics, pharmacological action, and clinical application of anisodamine.
Peng, C; Peng, F; Wan, F; Zhang, Y; Zou, J, 2023
)
2.57
"Anisodamine is a belladonna alkaloid, and like other drugs from this family is non subtype-selective muscarinic, and a nicotinic cholinoceptor antagonist, which has been employed in traditional Chinese medicine."( Possible role for anisodamine in organophosphate poisoning.
Eisenkraft, A; Falk, A, 2016
)
1.49
"Anisodamine is an ancient Chinese medicine derived from Tibet as a belladonna alkaloid, which is usually used for improvement of blood circulation in patients with organ phosphorus poisoning or shock. "( Cardioprotective Effect of Anisodamine Against Myocardial Ischemia Injury and its Influence on Cardiomyocytes Apoptosis.
Bai, S; Bi, X; Fu, X; Ge, X; Geng, W; Gu, X; Hao, G; Jiang, L; Li, W; Miao, Q; Peng, Y; Wang, Y; Wei, L; Xing, K, 2015
)
2.16
"Anisodamine is a multi-functional bio-alkaloid with vascular activity. "( Inhibition of endoplasm reticulum stress by anisodamine protects against myocardial injury after cardiac arrest and resuscitation in rats.
Shen, H; Yang, Y; Yin, XL; Zhang, W, 2011
)
2.07
"Anisodamine (aniso) is a peripheral muscarinic blocker isolated from a Chinese herb Anisodus tanguticus and is widely used in China."( Differentiating effects of anisodamine on cognitive amelioration and peripheral muscarinic side effects induced by pilocarpine in mice.
Chen, HZ; Lu, Y; Wang, H, 2003
)
1.34
"Anisodamine is a naturally occurring atropine derivative that has been isolated, synthesized and characterized by scientists in the People's Republic of China. "( The pharmacological properties of anisodamine.
Baskin, SI; Moore, E; Poupko, JM,
)
1.85
"Anisodamine hydrochloride is a vasoactive drug produced in the People's Republic of China that appears efficacious in clinical and experimental bacteremic shock, and about whose mode of action little is known. "( Anisodamine inhibits thromboxane synthesis, granulocyte aggregation, and platelet aggregation. A possible mechanism for its efficacy in bacteremic shock.
Coppo, PA; Hammerschmidt, DE; Jacob, HS; Xiu, RJ, 1982
)
3.15
"Anisodamine is an alkaloid isolated from a Chinese plant, which was subsequently synthesized. "( Protective effect of anisodamine on reperfusion injury of skeletal muscles in rabbit.
Han, L; Wei, X; Wei, Y; Zhang, Z, 1998
)
2.06
"Anisodamine is a natural alkaloid drug isolated from the plant Anisodus tanguticus growing in western China. "( Anisodamine as an effective drug to treat snakebites.
Li, QB; Pan, R; Tang, SX; Wang, GF, 1999
)
3.19
"Anisodamine is a tropane alkaloid isolated from the plant Anisodus tanguticus (Maxim) Pasch. "( [Studies on the determination of plasma level and pharmacokinetic parameters of anisodamine by micellar liquid chromatography].
Ma, P; Wu, CY, 1992
)
1.95
"Anisodamine is an alkaloid extracted from the Tibetan plant "Anisodus tanguticus". "( [Dopaminergic effect of anisodamine on the microcirculation of the hydronephrotic kidney of rats].
Parekh, N; Steinhausen, M; Zou, AP, 1991
)
2.03
"Anisodamine (Ani) is an alkaloid first isolated in China from the root of Anisodus tanguticus. "( [Anti-arrhythmia and vegetative nervous system effects of anisodamine].
Hong, N; Yang, P; Zhang, BH, 1991
)
1.97
"Anisodamine is a tropine alkaloid isolated from Scopolia tangutica Maxim. "( [Sites of seizure discharges after intracerebroventricular injection of anisodamine and the antagonism by diazepam in rabbits].
Jin, LR; Peng, JZ, 1989
)
1.95

Effects

Anisodamine has been shown to interact with and disrupt liposome structure. It has inhibitory effects on neuronal death and OH.production during cerebral ischemia-reperfusion in gerbils.

ExcerptReferenceRelevance
"Anisodamine has a promising therapeutic effect for septic shock."( Anisodamine Enhances Macrophage M2 Polarization through Suppressing G9a-Mediated Interferon Regulatory Factor 4 Silencing to Alleviate Lipopolysaccharide-Induced Acute Lung Injury.
Du, N; Li, K; Peng, Z; Ren, H; Song, D; Sun, X; Tang, SC; Wang, R; Zhang, Y, 2022
)
2.89
"Anisodamine has a promising therapeutic effect for septic shock."( Anisodamine Enhances Macrophage M2 Polarization through Suppressing G9a-Mediated Interferon Regulatory Factor 4 Silencing to Alleviate Lipopolysaccharide-Induced Acute Lung Injury.
Du, N; Li, K; Peng, Z; Ren, H; Song, D; Sun, X; Tang, SC; Wang, R; Zhang, Y, 2022
)
2.89
"Anisodamine has been shown to interact with and disrupt liposome structure which may reflect its effects on cellular membranes."( The pharmacological properties of anisodamine.
Baskin, SI; Moore, E; Poupko, JM,
)
1.13
"Anisodamine has inhibitory effects on neuronal death and OH.production during cerebral ischemia-reperfusion in gerbils."( Anisodamine protects against neuronal death following cerebral ischemia in gerbils.
Chen, Q; Zeng, Y, 2000
)
3.19

Actions

Anisodamine plays an immunomodulatory role by affecting the balance of Th17/Treg cytokines in resuscitated animals, so as to reduce the risk of intestinal secondary infection and has an organ protective effect. So Anisodamines can increase the survival rate of flaps with ischemia reperfusion injury.

ExcerptReferenceRelevance
"Anisodamine plays an immunomodulatory role by affecting the balance of Th17/Treg cytokines in resuscitated animals, so as to reduce the risk of intestinal secondary infection and has an organ protective effect."( [Study on anisodamine hydrobromide improves Th17/Treg imbalance in resuscitated pigs].
Dong, G; Mei, X; Yang, J; Zhao, X, 2022
)
2.57
"So Anisodamine can increase the survival rate of flaps with ischemia reperfusion injury."( [Experimental study on the protective effect of anisodamine on flaps with ischemia reperfusion injury].
Chen, YB; Dai, F; Lu, Q; Qiu, SL, 2013
)
1.16
"Anisodamine can inhibit hepatic fibrosis."( Antifibrotic activity of anisodamine in vivo is associated with changed intrahepatic levels of matrix metalloproteinase-2 and its inhibitor tissue inhibitors of metalloproteinases-2 and transforming growth factor beta1 in rats with carbon tetrachloride-in
Luo, L; Zhou, A, 2009
)
2.1
"Anisodamine did not increase superior mesenteric artery flow ( SMAF ) in this model of hemorrhagic shock as there was no significant difference in SMAF between the two shocked groups."( Beneficial effect of anisodamine in hemorrhagic shock.
Hock, CE; Lefer, AM; Su, J, 1984
)
1.31
"Anisodamine induced a lower percentage of death in Stx2-injected mice."( Anisodamine inhibits shiga toxin type 2-mediated tumor necrosis factor-alpha production in vitro and in vivo.
Ou, ZL; Yamamoto, T; Zhang, HM, 2001
)
2.47
"The anisodamine can inhibit the decrease of deformability of PMN effectively and may have some therapeutic effect on ALI."( [Changes of the deformability of neutrophil and the influence of anisodamine on neutrophil deformability during endotoxin-induced acute lung injury in rats].
Qian, G; Sun, G; Xu, X, 1998
)
1.02

Treatment

Anisodamine adjuvant treatment of acute serous otitis media by improving the function of eustachian tube and microcirculation. Treatment with anisodamines ameliorated renal I/R injury, as evidenced by improvements of renal histology and kidney function.

ExcerptReferenceRelevance
"Anisodamine treatment decreases the expression of caspase-3 and caspase-8, and increases Bcl-2/Bax ratio in cardiomyocytes."( Cardioprotective Effect of Anisodamine Against Myocardial Ischemia Injury and its Influence on Cardiomyocytes Apoptosis.
Bai, S; Bi, X; Fu, X; Ge, X; Geng, W; Gu, X; Hao, G; Jiang, L; Li, W; Miao, Q; Peng, Y; Wang, Y; Wei, L; Xing, K, 2015
)
1.44
"Anisodamine adjuvant treatment of acute serous otitis media by improving the function of eustachian tube and microcirculation."( [Adjuvant treatment of anisodamine to acute serous otitis media].
Jiang, Z; Liu, W; Zhang, L; Zhao, C, 2004
)
2.08
"Anisodamine treated shock cats exhibited significantly lower cathepsin D activity (P less than 0.02) and amino-nitrogen concentration (P less than 0.001) than untreated shock animals."( Beneficial effect of anisodamine in hemorrhagic shock.
Hock, CE; Lefer, AM; Su, J, 1984
)
1.31
"In anisodamine treatment group, the Bmax of beta receptor (529 +/- 113) and content of cAMP was higher significantly (P < 0.01) than that of the untreated group."( [A study on changes of adrenergic receptors and their clinical significance in the lung of rats with respiratory distress syndrome].
Liu, YM, 1993
)
0.8
"Anisodamine treatment prolonged the survival time of mice and decreased the lethality of Stx1 (94.5% to 44%)."( Protective effect of anisodamine against Shiga toxin-1: inhibition of cytokine production and increase in the survival of mice.
Gondaira, F; Kojio, S; Ohmura, M; Ou, ZL; Yamamoto, T; Zhang, HM, 2001
)
1.35
"Treatment with anisodamine ameliorated renal I/R injury, as evidenced by improvements of renal histology and kidney function, a decrease in paller's score and apoptosis index."( Anisodamine ameliorates ischemia/reperfusion-induced renal injury in rats through activation of the extracellular signal-regulated kinase (ERK) pathway and anti-apoptotic effect.
Huang, Y; Ji, H; Jin, C; Sun, D; Sun, S; Xia, A; Xu, X; Zhang, S, 2021
)
2.4
"Pretreatment with anisodamine ameliorates renal dysfunction in the rat model of glycerol-induced rhabdomyolytic kidney injury by reducing oxidative stress, the inflammatory response and cell death."( Protective effect of anisodamine in rats with glycerol-induced acute kidney injury.
An, LP; An, R; Du, XF; Li, YF; Sun, JH; Wang, W; Wu, GL; Xu, BY; Yu, K; Zhang, GH, 2019
)
1.17
"Treatment with anisodamine or methylprednisolone significantly inhibited the increases of parameters of ALI induced by LPS, and markedly reduced the expression of IL-17A and IL-17F in rats and the IL-17F expression in PMVEC."( Expression of IL-17A and IL-17F in lipopolysaccharide-induced acute lung injury and the counteraction of anisodamine or methylprednisolone.
Niu, CC; Sun, GY; Wang, N; You, QH; Yue, Y; Zhang, D; Zhu, ZM, 2014
)
0.96
"Pretreatment with anisodamine increased heart rate from 163 +/- 15 to 289 +/- 10 beats.min-1 and cardiac index from 195 +/- 15 to 238 +/- 14 mL.min-1.kg-1 before endotoxin infusion."( Effects of cholinergic blockade on hemodynamic disturbances and intestinal lesions in endotoxic shock in newborn piglets.
Grantham, KD; Kelly, DR; Li, JX; Oliver, JR; Philips, JB, 1994
)
0.61
"Pretreatment with anisodamine 25 mg.kg-1 ig bid for 3 d decreased the incidence of ulcers in all of these models."( [Anti-ulcer effect of anisodamine in rats].
Geng, BQ; Gu, GG; Yong, DG; Yu, WH; Zhong, FM, 1991
)
0.92

Toxicity

ExcerptReferenceRelevance
" However, dose-limiting adverse effects restrict its tolerability and clinical outcomes."( Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine.
Chen, HZ; Cui, YY; Li, J; Shao, BY; Song, MK; Wang, H; Xia, Z; Xu, ZP; Zhang, WW, 2009
)
0.63
" The percentage of patients with at least one adverse event was lower in the HBB group than in the anisodamine group (13."( Comparison of efficacy and safety of hyoscine butylbromide versus anisodamine for acute gastric or intestinal spasm-like pain: A randomized, double-blinded, multicenter Phase III trial.
Du, YQ; Guo, XZ; Hou, XH; Jiang, F; Li, ZS; Wang, RQ; Xu, H; Zeng, Y; Zhu, CP, 2017
)
0.91
" Both drugs were safe and well tolerated."( Comparison of efficacy and safety of hyoscine butylbromide versus anisodamine for acute gastric or intestinal spasm-like pain: A randomized, double-blinded, multicenter Phase III trial.
Du, YQ; Guo, XZ; Hou, XH; Jiang, F; Li, ZS; Wang, RQ; Xu, H; Zeng, Y; Zhu, CP, 2017
)
0.69

Pharmacokinetics

Anisodamine enantiomers showed non-stereoselective disposition in rabbits. Study of anisodamines pharmacokinetic in man was also described.

ExcerptReferenceRelevance
" The study of anisodamine pharmacokinetic in man was also described."( [Studies on the determination of plasma level and pharmacokinetic parameters of anisodamine by micellar liquid chromatography].
Ma, P; Wu, CY, 1992
)
0.87
" Pharmacokinetic analysis of results indicated that anisodamine enantiomers showed non-stereoselective disposition or stereoselective disposition in different rabbits."( Study of stereoselective pharmacokinetics of anisodamine enantiomers in rabbits by capillary electrophoresis.
Fan, GR; Hong, ZY; Lin, M; Wu, YT; Yin, XP, 2004
)
0.83
" Clinical phenomena suggested that the changes of substituent group were related to the pharmacokinetic and pharmacodynamic characteristics of the agents."( Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats.
Chen, X; Li, C; Li, N; Liu, Q; Lu, Y; Ren, S; Tian, F; Wang, X; Zhao, D; Zhou, S, 2015
)
0.64
" The pharmacokinetic parameters revealed areas under the curve of 22."( Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study.
Deng, X; Li, Y; Liao, Q; Liu, G; Sun, X; Xie, Z; Zhang, P; Zhou, Y, 2014
)
0.65
"This review describes the relevant pharmacokinetic parameters."( Update on the sources, pharmacokinetics, pharmacological action, and clinical application of anisodamine.
Peng, C; Peng, F; Wan, F; Zhang, Y; Zou, J, 2023
)
1.13

Compound-Compound Interactions

The effects of bepridil (Bep) in combination with anisodamine (Ani) on myocardial ischemia and reperfusion injury induced by ligating the left coronary artery were studied in rats.

ExcerptReferenceRelevance
"The effects of bepridil (Bep) in combination with anisodamine (Ani) on myocardial ischemia and reperfusion injury induced by ligating the left coronary artery were studied in rats."( [Protective effects of bepridil in combination with anisodamine on myocardial ischemia and reperfusion injury in rats].
Chen, JM; Cui, JY; Dong, HY; Gu, SL; Peng, ZY; Zhou, J, 1995
)
0.79
" Also, the merit of cardioprotection by DADLE in combination with anisodamine, the muscarinic receptor antagonist (D+M), was evaluated."( Merit of anisodamine combined with opioid δ-receptor activation in the protection against myocardial injury during cardiopulmonary bypass.
Chan, P; Fan, H; Hong, X; Liu, Z; Lu, R, 2013
)
1.04
"Hepatectomy followed by choledochoendoscopic stone extraction without biliary drainage is a safe and effective treatment of hepatolithiasis combined with choledocholithiasis."( Hepatectomy with primary closure of common bile duct for hepatolithiasis combined with choledocholithiasis.
Chen, YK; Fu, Y; Jia, CK; Qin, QF; Weng, J; Yang, QZ; Yu, WM, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21."( Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats.
Chen, X; Li, C; Li, N; Liu, Q; Lu, Y; Ren, S; Tian, F; Wang, X; Zhao, D; Zhou, S, 2015
)
0.64
" Anisodamine is poorly absorbed in the gastrointestinal tract, and it is not as effective as intravenous administration."( Update on the sources, pharmacokinetics, pharmacological action, and clinical application of anisodamine.
Peng, C; Peng, F; Wan, F; Zhang, Y; Zou, J, 2023
)
2.04
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" After CPR for 4 minutes the animals in control group received normal saline, group epinephrine (Epi) received Epi (bolus dose of 200 microg/kg), Epi plus low dosage Ani (Ld Ani) group received Epi plus Ani (bolus dose of 200 microg/kg Epi followed by Ani of 5 mg/kg), and Epi plus high dosage Ani (Hd Ani) group received Epi plus Ani (bolus dose of 200 microg/kg Epi followed by Ani of 10 mg/kg)."( [Effects of anisodamine on microcirculation of the asystole rats during the cardiopulmonary resuscitation].
Chen, W; Ji, D; Jia, LJ; Liu, XH; Shen, H; Zhao, XM, 2008
)
0.72
" All patients in treatment group received anisodamine in small dosage 2 hours before extubation."( [Investigation of adjuvant treatment for difficult weaning from mechanical ventilation].
Bai, Y; Jia, L; Li, H; Zhu, X, 2014
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (334)

TimeframeStudies, This Drug (%)All Drugs %
pre-199094 (28.14)18.7374
1990's77 (23.05)18.2507
2000's61 (18.26)29.6817
2010's76 (22.75)24.3611
2020's26 (7.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.78 (24.57)
Research Supply Index5.91 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index45.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (9.23%)5.53%
Trials0 (0.00%)5.53%
Reviews11 (3.27%)6.00%
Reviews0 (0.00%)6.00%
Case Studies8 (2.38%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other286 (85.12%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effectiveness of Anisodamine for the Treatment of Critically Ill Patients With Septic Shock: a Randomized Controlled Trial [NCT02442440]Phase 1/Phase 2355 participants (Actual)Interventional2015-04-30Completed
Evaluation of the Efficacy of Anisodamine Hydrobromide Combined With Heparin in the Treatment of Patients With Critical Infection [NCT05634057]782 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation [NCT06045364]Phase 1/Phase 2130 participants (Anticipated)Interventional2023-10-01Not yet recruiting
A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) [NCT01929044]Phase 3299 participants (Actual)Interventional2013-08-31Completed
FOLFOX Via Hepatic Artery Infusion Chemotherapy (HAI) Plus Systemic Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A [NCT05727163]Phase 2194 participants (Anticipated)Interventional2022-07-29Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01929044 (7) [back to overview]PID From Pre-dose Baseline at 10 Minutes After First Injection.
NCT01929044 (7) [back to overview]PID From Pre-dose Baseline at 120 Minutes After First Injection.
NCT01929044 (7) [back to overview]PID From Pre-dose Baseline at 20 Minutes After First Injection.
NCT01929044 (7) [back to overview]PID From Pre-dose Baseline at 30 Minutes After First Injection.
NCT01929044 (7) [back to overview]PID From Pre-dose Baseline at 60 Minutes After First Injection.
NCT01929044 (7) [back to overview]Proportion of Patients Who Need the Second Injection
NCT01929044 (7) [back to overview]Global Assessment of Efficacy by the Patient at 120 Minutes After the First Injection

PID From Pre-dose Baseline at 10 Minutes After First Injection.

Pain intensity difference (PID) from pre-dose baseline at 10 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'. (NCT01929044)
Timeframe: Baseline and 10 minutes after the first injection

InterventionUnits on a scale (Least Squares Mean)
Buscopan® (Hyoscine Butylbromide)-2.64
654-II (Anisodamine)-2.33

[back to top]

PID From Pre-dose Baseline at 120 Minutes After First Injection.

Pain intensity difference (PID) from pre-dose baseline at 120 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'. (NCT01929044)
Timeframe: Baseline and 120 minutes after the first injection

InterventionUnits on a scale (Least Squares Mean)
Buscopan® (Hyoscine Butylbromide)-6.46
654-II (Anisodamine)-6.01

[back to top]

PID From Pre-dose Baseline at 20 Minutes After First Injection.

Pain intensity difference (PID) from pre-dose baseline at 20 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'. (NCT01929044)
Timeframe: Baseline and 20 minutes after the first injection

InterventionUnits on a scale (Least Squares Mean)
Buscopan® (Hyoscine Butylbromide)-4.09
654-II (Anisodamine)-3.66

[back to top]

PID From Pre-dose Baseline at 30 Minutes After First Injection.

Pain intensity difference (PID) from pre-dose baseline at 30 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'. (NCT01929044)
Timeframe: Baseline and 30 minutes after the first injection

InterventionUnits on a scale (Least Squares Mean)
Buscopan® (Hyoscine Butylbromide)-5.14
654-II (Anisodamine)-4.74

[back to top]

PID From Pre-dose Baseline at 60 Minutes After First Injection.

Pain intensity difference (PID) from pre-dose baseline at 60 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'. (NCT01929044)
Timeframe: Baseline and 60 minutes after the first injection

InterventionUnits on a scale (Least Squares Mean)
Buscopan® (Hyoscine Butylbromide)-5.96
654-II (Anisodamine)-5.51

[back to top]

Proportion of Patients Who Need the Second Injection

Proportion of patients who need the second injection at 20 minutes after the first injection. (NCT01929044)
Timeframe: 20 minutes after the first injection.

InterventionPercentage of Patients (Number)
Buscopan® (Hyoscine Butylbromide)24.6
654-II (Anisodamine)33.9

[back to top]

Global Assessment of Efficacy by the Patient at 120 Minutes After the First Injection

"Global assessment of efficacy by the patient. The patient was to assess the efficacy at 120 min after the first injection using a 4-point rating scale by answering the question: How would you rate the effect of the study medication for relieving your acute gastric or intestinal spasm-like pain? (0 = poor; 1 = fair; 2 = good; 3 = very good)." (NCT01929044)
Timeframe: 120 minutes after the first injection

,
InterventionPercentage of Patients (Number)
Very GoodGoodFairPoor
654-II (Anisodamine)22.044.129.14.7
Buscopan® (Hyoscine Butylbromide)22.559.218.30.0

[back to top]